A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants

Clinical Pharmacology and Therapeutics

Volumn 79, Issue 1, 2006, Pages 103-113

  Sim, Sarah C ^a   Risinger, Carl ^b   Dahl, Marja Liisa ^b   Aklillu, Eleni ^b   Christensen, Magnus ^b   Bertilsson, Leif ^b   Ingelman Sundberg, Magnus ^b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; CYTOCHROME P450 2C19; MEPHENYTOIN; NUCLEAR PROTEIN; OMEPRAZOLE; PROTON PUMP INHIBITOR;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CLONING; CONTROLLED STUDY; DRUG METABOLISM; DRUG RESPONSE; GEL MOBILITY SHIFT ASSAY; GENE CONSTRUCT; GENETIC TRANSFECTION; GENOTYPE PHENOTYPE CORRELATION; HUMAN; HUMAN EXPERIMENT; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; RACE DIFFERENCE; REPORTER GENE; SEQUENCE ANALYSIS; STATISTICAL ANALYSIS; TRANSCRIPTION INITIATION;

ANIMALS; ANTICONVULSANTS; ANTIDEPRESSIVE AGENTS; ARYL HYDROCARBON HYDROXYLASES; CHINA; ELECTROPHORETIC MOBILITY SHIFT ASSAY; ENZYME INHIBITORS; ETHIOPIA; GENE FREQUENCY; GENES, REPORTER; GENOTYPE; HUMANS; MALE; MEPHENYTOIN; MICE; MIXED FUNCTION OXYGENASES; MUTATION; OMEPRAZOLE; PHENOTYPE; PLASMIDS; PROTON PUMPS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SWEDEN; TRANSFECTION; VARIATION (GENETICS);

EID: 30344457586     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clpt.2005.10.002     Document Type: Article

References (48)

1. W.E. Evans, M.V. Relling Pharmacogenomics translating functional genomics into rational therapeutics Science 286 1999 487 491
2. U. Klotz, M. Schwab, G. Treiber CYP2C19 polymorphism and proton pump inhibitors Basic Clin Pharmacol Toxicol 95 2004 2 8
3. Z. Desta, X. Zhao, J.G. Shin, D.A. Flockhart Clinical significance of the cytochrome P450 2C19 genetic polymorphism Clin Pharmacokinet 41 2002 913 958
4. J. Kirchheiner, K. Nickchen, M. Bauer, M.L. Wong, J. Licinio, I. Roots, J. Brockmoller Pharmacogenetics of antidepressants and antipsychotics the contribution of allelic variations to the phenotype of drug response Mol Psychiatry 9 2004 442 473
5. S. Ozawa, A. Soyama, M. Saeki, H. Fukushima-Uesaka, M. Itoda, S. Koyano Ethnic differences in genetic polymorphisms of CYP2D6, CYP2C19, CYP3As and MDR1/ABCB1 Drug Metab Pharmacokinet 19 2004 83 95
6. N. Shirai, T. Furuta, Y. Moriyama, H. Okochi, K. Kobayashi, M. Takashima Effects of CYP2C19 genotypic differences in the metabolism of omeprazole and rabeprazole on intragastric pH Aliment Pharmacol Ther 15 2001 1929 1937
7. T. Furuta, K. Ohashi, K. Kosuge, X.J. Zhao, M. Takashima, M. Kimura CYP2C19 genotype status and effect of omeprazole on intragastric pH in humans Clin Pharmacol Ther 65; 1999 552 561
8. M. Schwab, E. Schaeffeler, U. Klotz, G. Treiber CYP2C19 polymorphism is a major predictor of treatment failure in white patients by use of lansoprazole-based quadruple therapy for eradication of Helicobacter pylori Clin Pharmacol Ther 76 2004 201 209
9. T. Furuta, N. Shirai, M. Sugimoto, K. Ohashi, T. Ishizaki Pharmacogenomics of proton pump inhibitors Pharmacogenomics 5 2004 181 202
10. T. Furuta, K. Ohashi, T. Kamata, M. Takashima, K. Kosuge, T. Kawasaki Effect of genetic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer Ann Intern Med 129 1998 1027 1030
11. T. Furuta, N. Shirai, F. Watanabe, S. Honda, K. Takeuchi, T. Iida Effect of cytochrome P4502C19 genotypic differences on cure rates for gastroesophageal reflux disease by lansoprazole Clin Pharmacol Ther 72 2002 453 460
12. M. Kawamura, S. Ohara, T. Koike, K. Iijima, J. Suzuki, S. Kayaba The effects of lansoprazole on erosive reflux oesophagitis are influenced by CYP2C19 polymorphism Aliment Pharmacol Ther 17 2003 965 973
13. M. Chang, M.L. Dahl, G. Tybring, E. Gotharson, L. Bertilsson Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype Pharmacogenetics 5 1995 358 363
14. M.J. Kim, J.S. Bertino, A. Gaedigk, Y. Zhang, E.M. Sellers, A.N. Nafziger Effect of sex and menstrual cycle phase on cytochrome P450 2C19 activity with omeprazole used as a biomarker Clin Pharmacol Ther 72 2002 192 199
15. CYP2C19 allele nomenclature. Available from: URL: http://www.imm.ki.se/ CYPalleles/cyp2c19.htm. Accessed Nov 2005.
16. J. Blaisdell, H. Mohrenweiser, J. Jackson, S. Ferguson, S. Coulter, B. Chanas Identification and functional characterization of new potentially defective alleles of human CYP2C19 Pharmacogenetics 12 2002 703 711
17. M. Arefayene, T.C. Skaar, X. Zhao, J.M. Rae, J.E. Tanus-Santos, U. Brinkmann Sequence diversity and functional characterization of the 5'-regulatory region of human CYP2C19 Pharmacogenetics 13 2003 199 206
18. M. Christensen, K. Andersson, P. Dalen, R.A. Mirghani, G.J. Muirhead, A. Nordmark The Karolinska cocktail for phenotyping of five human cytochrome P450 enzymes Clin Pharmacol Ther 73 2003 517 528
19. I. Yue Q.Y. Johansson, M.L. Dahl, M. Heim, J. Sawe, L. Bertilsson Genetic analysis of the interethnic difference between Chinese and Caucasians in the polymorphic metabolism of debrisoquine and codeine Eur J Clin Pharmacol 40 1991 553 556
20. I. Persson, E. Aklillu, F. Rodrigues, L. Bertilsson, M. Ingelman-Sundberg S-mephenytoin hydroxylation phenotype and CYP2C19 genotype among Ethiopians Pharmacogenetics 6 1996 521 526
21. E. Aklillu, K. Herrlin, L.L. Gustafsson, L. Bertilsson, M. Ingelman-Sundberg Evidence for environmental influence on CYP2D6-catalysed debrisoquine hydroxylation as demonstrated by phenotyping and genotyping of Ethiopians living in Ethiopia or in Sweden Pharmacogenetics 12 2002 375 383
22. H. Nakabayashi, T. Hashimoto, Y. Miyao, K.K. Tjong, J. Chan, T. Tamaoki A position-dependent silencer plays a major role in repressing alpha-fetoprotein expression in human hepatoma Mol Cell Biol 11 1991 5885 5893
23. Home page of the Human Cytochrome P450 (CYP) Allele Nomenclature Committee. Available from: URL: http://www.imm.ki.se/CYPalleles/. Accessed Nov 2005.
24. K. Laine, G. Tybring, L. Bertilsson No sex-related differences but significant inhibition by oral contraceptives of CYP2C19 activity as measured by the probe drugs mephenytoin and omeprazole in healthy Swedish white subjects Clin Pharmacol Ther 68 2000 151 159
25. W.J. Tamminga, J. Wemer, B. Oosterhuis, J. Weiling, B. Wilffert, L.F. de Leij CYP2D6 and CYP2C19 activity in a large population of Dutch healthy volunteers indications for oral contraceptive-related gender differences Eur J Clin Pharmacol 55 1999 177 184
26. M. Chang, G. Tybring, M.L. Dahl, E. Gotharson, M. Sagar, R. Seensalu Interphenotype differences in disposition and effect on gastrin levels of omeprazole - suitability of omeprazole as a probe for CYP2C19 Br J Clin Pharmacol 39 1995 511 518
27. M. Sagar, G. Tybring, M.L. Dahl, L. Bertilsson, R. Seensalu Effects of omeprazole on intragastric pH and plasma gastrin are dependent on the CYP2C19 polymorphism Gastroenterology 119 2000 670 676
28. E. Suzuki, T. Evans, J. Lowry, L. Truong, D.W. Bell, J.R. Testa The human GATA-6 gene structure, chromosomal location, and regulation of expression by tissue-specific and mitogen-responsive signals Genomics 38 1996 283 290
29. C. Dame, M.C. Sola, K.C. Lim, K.M. Leach, J. Fandrey, Y. Ma Hepatic erythropoietin gene regulation by GATA-4 J Biol Chem 279 2004 2955 2961
30. J.K. Divine, L.J. Staloch, H. Haveri, C.M. Jacobsen, D.B. Wilson, M. Heikinheimo GATA-4, GATA-5, and GATA-6 activate the rat liver fatty acid binding protein gene in concert with HNF-1{alpha} Am J Physiol Gastrointest Liver Physiol 287 2004 G1086 G1099
31. Q.S. Zhu, B. Qian, D. Levy Regulation of human microsomal epoxide hydrolase gene (EPHX1) expression by the transcription factor GATA-4 Biochim Biophys Acta 1676 2004 251 260
32. TESS transcription element search system. Available from: URL: http://www.cbil.upenn.edu/tess. Accessed Feb 2005.
33. O.Q. Yin, B. Tomlinson, A.H. Chow, M.M. Waye, M.S. Chow Omeprazole as a CYP2C19 marker in Chinese subjects assessment of its gene-dose effect and intrasubject variability J Clin Pharmacol 44 2004 582 589
34. T. Furuta, N. Shirai, M. Takashima, F. Xiao, H. Hanai, K. Nakagawa Effects of genotypic differences in CYP2C19 status on cure rates for Helicobacter pylori infection by dual therapy with rabeprazole plus amoxicillin Pharmacogenetics 11 2001 341 348
35. S. Take, M. Mizuno, K. Ishiki, Y. Nagahara, T. Yoshida, T. Inaba Interleukin-1beta genetic polymorphism influences the effect of cytochrome P 2C19 genotype on the cure rate of 1-week triple therapy for Helicobacter pylori infection Am J Gastroenterol 98 2003 2403 2408
36. T. Furuta, N. Shirai, M. Takashima, F. Xiao, H. Hanai, H. Sugimura Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin Clin Pharmacol Ther 69 2001 158 168
37. T. Furuta, N. Shirai, F. Xiao, K. Ohashi, T. Ishizaki Effect of high-dose lansoprazole on intragastric pH in subjects who are homozygous extensive metabolizers of cytochrome P4502C19 Clin Pharmacol Ther 70 2001 484 492
38. M. Sugimoto, T. Furuta, N. Shirai, M. Kajimura, A. Hishida, M. Sakurai Different dosage regimens of rabeprazole for nocturnal gastric acid inhibition in relation to cytochrome P450 2C19 genotype status Clin Pharmacol Ther 76 2004 290 301
39. T. Kita, T. Sakaeda, N. Aoyama, T. Sakai, Y. Kawahara, M. Kasuga Optimal dose of omeprazole for CYP2C19 extensive metabolizers in anti-Helicobacter pylori therapy pharmacokinetic considerations Biol Pharm Bull 25 2002 923 927
40. K.S. Yu, D.S. Yim, J.Y. Cho, S.S. Park, J.Y. Park, K.H. Lee Effect of omeprazole on the pharmacokinetics of moclobemide according to the genetic polymorphism of CYP2C19 Clin Pharmacol Ther 69 2001 266 273
41. T. Noguchi, K. Shimoda, S. Takahashi Clinical significance of plasma levels of clomipramine, its hydroxylated and desmethylated metabolites prediction of clinical outcome in mood disorders using discriminant analysis of therapeutic drug monitoring data J Affect Disord 29 1993 267 279
42. A. Yokono, S. Morita, T. Someya, G. Hirokane, M. Okawa, K. Shimoda The effect of CYP2C19 and CYP2D6 genotypes on the metabolism of clomipramine in Japanese psychiatric patients J Clin Psychopharmacol 21 2001 549 555
43. J.H. Wang, Z.Q. Liu, W. Wang, X.P. Chen, Y. Shu, N. He Pharmacokinetics of sertraline in relation to genetic polymorphism of CYP2C19 Clin Pharmacol Ther 70 2001 42 47
44. K. Herrlin, N. Yasui-Furukori, G. Tybring, J. Widen, L.L. Gustafsson, L. Bertilsson Metabolism of citalopram enantiomers in CYP2C19/CYP2D6 phenotyped panels of healthy Swedes Br J Clin Pharmacol 56 2003 415 421
45. B.N. Yu, G.L. Chen, N. He, D.S. Ouyang, X.P. Chen, Z.Q. Liu Pharmacokinetics of citalopram in relation to genetic polymorphism of CYP2C19 Drug Metab Dispos 31 2003 1255 1259
46. R.M. Berman, M. Narasimhan, D.S. Charney Treatment-refractory depression definitions and characteristics Depress Anxiety 5 1997 154 164
47. D.P. Devanand, G.H. Pelton, K. Marston, Y. Camacho, S.P. Roose, Y. Stern Sertraline treatment of elderly patients with depression and cognitive impairment Int J Geriatr Psychiatry 18 2003 123 130
48. K.M. Smits, L.J. Smits, J.S. Schouten, F.F. Stelma, P. Nelemans, M.H. Prins Influence of SERTPR and STin2 in the serotonin transporter gene on the effect of selective serotonin reuptake inhibitors in depression a systematic review Mol Psychiatry 9 2004 433 441